Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur J Haematol ; 74(6): 481-8, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15876251

RESUMEN

OBJECTIVES: Ku, a heterodimer of KU70 and Ku80 that binds to double-strand DNA breaks (DSBs) and activates the catalytic subunit (DNA-PKcs) when DNA is bound, is essential in DSB repair and V(D)J recombination. Ku80 is a putative tumor suppressor gene that might play an important role in drug resistance. Our aim was to determine the role of Ku80 in lymphoid malignancy. PATIENTS AND METHODS: Competitive reverse transcription-polymerase chain reaction assays were performed and the expression levels of Ku80 were measured in normal peripheral blood mononuclear cells (n = 9) and malignant cells from 25 patients with acute lymphoblastic leukemia (ALL) (14 children, 11 adults), and chronic lymphoproliferative disorders (n = 6). The Ku80 transcripts were sequencing for the possibility of mutation. RESULTS: No mutation or Ku80 variant at the RNA level was seen in any patient samples or in the Raji or CCRF-CEM cell lines. In Ku80 expression, 8.8-, 1.9-, and 6.2-fold mean increases were seen in adult, pediatric ALL, and chronic lymphoid malignancies compared with the control. The Ku80 was significantly higher in adult than in pediatric ALL (P = 0.02). The amount of Ku80 expression in ALL was moderately correlated with peripheral white blood cell counts, but not with Ki67 labeling index. High Ku80 expressers (higher than the mean of all patients with ALL) tended to respond poorly to therapy: Only 22% of high Ku80 expressers achieved durable complete remission compared to 62% of low expressers. CONCLUSIONS: Our study suggests that Ku80 might contribute to generally poor prognoses in adult ALL.


Asunto(s)
Antígenos Nucleares/biosíntesis , Reparación del ADN/genética , Proteínas de Unión al ADN/biosíntesis , Regulación Leucémica de la Expresión Génica , Leucemia Linfocítica Crónica de Células B/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Adolescente , Adulto , Antígenos Nucleares/genética , Línea Celular Tumoral , Niño , Preescolar , Proteínas de Unión al ADN/genética , Humanos , Lactante , Antígeno Ki-67/biosíntesis , Antígeno Ki-67/genética , Autoantígeno Ku , Leucemia Linfocítica Crónica de Células B/patología , Leucocitos Mononucleares/metabolismo , Masculino , Persona de Mediana Edad , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Pronóstico , ARN Mensajero/biosíntesis , ARN Mensajero/genética
2.
Adv Ther ; 20(6): 337-43, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-15058751

RESUMEN

The effect of all-trans retinoid acid (ATRA) on the expression of Notch1 gene by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in acute promyelocytic leukemia cells (APL), NB4, and HL-60 lacking t(15;17) was studied. The cells were treated with ATRA 0.5 microM for up to 96 hours. The increased transcript level of Notch1 was in concert with that of CD11b in NB4 cells, but not in HL-60 cells. The expression of Notch1 gene might be specific for APL cells. As Notch1 gene is involved in the differentiation and leukemogenesis in lymphoid neoplasm, observations suggest that Notch1 is involved in ATRA-modulated differentiation process in APL.


Asunto(s)
Predisposición Genética a la Enfermedad , Leucemia Promielocítica Aguda/genética , Receptores de Superficie Celular/genética , Factores de Transcripción , Tretinoina/farmacología , Secuencia de Bases , División Celular/efectos de los fármacos , División Celular/fisiología , Femenino , Regulación Neoplásica de la Expresión Génica , Células HL-60/efectos de los fármacos , Células HL-60/fisiología , Humanos , Masculino , Datos de Secuencia Molecular , Proteínas de Neoplasias/genética , Receptor Notch1 , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Sensibilidad y Especificidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA